The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus

Pediatric Laryngopharyngeal Reflux: Epidemiology, Clinical Presentation, Diagnosis, and Therapeutic Outcomes

Gastroesophageal reflux (GER) involves retrograde transit of gastric contents into the esophagus, a physiologic, transient, and typically benign process in infants. By contrast, GER disease arises when reflux causes troublesome symptoms or complications. Laryngopharyngeal reflux (LPR)-a subset of extraesophageal reflux-occurs when gastric contents flow proximally to affect the larynx and pharynx. LPR in the pediatric population presents unique challenges due to incomplete understanding of its pathophysiology and overlapping signs and symptoms with other conditions. Multidisciplinary evaluation is crucial for accurate diagnosis and optimal treatment.

Effective Restoration of Gastric and Esophageal Tissues in an In Vitro Model of GERD: Mucoadhesive and Protective Properties of Xyloglucan, Pea Proteins, and Polyacrylic Acid

Esophageal barrier dysfunction is a crucial pathophysiological mechanism of gastroesophageal reflux disease (GERD). However, treatments mainly aim to reduce gastric acidity rather than improve tissue integrity. This study evaluated the protective and mucoadhesive properties of a formulation containing xyloglucan, pea proteins, and polyacrylic acid (XPPA) in gastric and esophageal cells. Cells were exposed to hydrochloric acid (HCl) and subsequently treated with the test compound. Trans-epithelial electrical resistance (TEER), tight junction (TJ) expression, and mucoadhesion of XPPA on gastric and esophageal cells were evaluated. To further confirm the protective ability of XPPA, a Lucifer Yellow assay was performed on a human reconstructed esophageal epithelium to assess the ability of XPPA to prevent HCl-induced hyperpermeability. XPPA possesses noteworthy mucoadhesive properties, ensuring an extended contact time between the product and the damaged mucosa to allow sustained mucosal protection. Furthermore, XPPA effectively restored gastroesophageal barrier integrity after HCl-induced damage, as assessed with TEER, after 1 h (p < 0.05). Finally, XPPA helped to restore TJ expression (p < 0.05) and protected the tissues from hyperpermeability for at least 2 h (p < 0.05). These results pave the way for using XPPA as a promising treatment to ameliorate gastroesophageal barrier properties in GERD patients.

Design and Development of a Specific Questionnaire for Assessing Gastrointestinal Quality of Life After Metabolic and Bariatric Surgery

BACKGROUND

The improvement of health-related quality of life (QoL) after metabolic and bariatric surgery (MBS) is an indicator of success. Due to alterations in the upper gastrointestinal (GI) tract after MBS, important changes occur in the GIQoL. Consequently, patients develop new GI symptoms that affect their lifestyle and interpersonal relationships (IIRR). Therefore, questionnaires specifically assessing GIQoL are necessary. This work aimed to design and validate a GIQoL.

METHODS

The questionnaire development process was divided into four phases. Phase I-II consisted of initial items generation through a literature review, expert consensus (Delphi study), and patient discussion groups (14 patients who underwent to BS). In Phase III, the results were analyzed qualitatively and unified, obtaining the "Questionnaire version 0." Currently, phase IV is in process, and it will consist of analysis its psychometric properties for its final validation.

RESULTS

After literature review, no GIQoL questionnaires were found in this type of patient. The Delphi study consensus was reached on 8 of 15 proposed items. Most patients recognized a general deterioration of their GIQoL compared to the period prior to surgery. The final questionnaire has 13 questions, covering 3 dimensions: GI and psychological symptomatology, the influence of the eating habits on daily life, and impact of BS on IIRR.

CONCLUSIONS

This article describes the process of developing a specific GIQoL questionnaire, which will be completed once we have carried out its psychometric analysis. This questionnaire fills a critical gap in the current assessment of GIQoL after MBS, offering a validated and specific tool that can be integrated into clinical practice.

Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis

BACKGROUND

Linaprazan glurate, a potassium-competitive acid blocker, is in development for the treatment of erosive oesophagitis and other acid-related diseases.

AIM

To evaluate the 4-week healing rate and safety of four linaprazan glurate dosing regimens in patients with erosive oesophagitis.

METHODS

This double-blind, dose-finding study compared linaprazan glurate to lansoprazole. We included patients with endoscopically confirmed erosive oesophagitis (validated by a central review board) if they had Los Angeles (LA) grade C/D or LA grade A/B with partial response to at least 8 weeks of proton pump inhibitor therapy. Patients were randomised to 4 weeks of linaprazan glurate (25, 50, 75 or 100 mg twice daily) or lansoprazole (30 mg once daily), followed by 4 weeks of open-label lansoprazole.

RESULTS

Of 248 patients randomised, central review confirmed erosive oesophagitis in 182 at screening endoscopy. Across all doses, linaprazan glurate achieved a 4-week healing rate of 71.1% in intention-to-treat (ITT) analysis and 80.9% in per protocol (PP) analysis. In comparison, lansoprazole achieved healing rates of 60.6% (ITT) and 59.1% (PPS). The best performing linaprazan glurate dosing group outperformed lansoprazole by 28% in patients with LA grade A/B with partial PPI response and by more than 50% in patients with LA grade C/D.

CONCLUSIONS

Linaprazan glurate demonstrated high 4-week healing rates compared to lansoprazole, with a good safety profile, supporting its further development.

TRIAL REGISTRATION

ClinicalTrials.gov: NCT05055128; EudraCT: 2020-003319-91.

A high arousal threshold is associated with nocturnal gastroesophageal reflux in obstructive sleep apnea

OBJECTIVE

Nocturnal gastroesophageal reflux (nGER) was reported to be associated with obstructive sleep apnea (OSA). However, pathophysiological traits in OSA patients with nGER were poorly understood, and arousal threshold (ArTH) might play an important role in this relationship. This study aimed to identify the clinical characteristics of patients with OSA comorbid with nGER, and investigate the association between ArTH and nGER in patients with OSA.

METHODS

482 adult patients with OSA diagnosed by polysomnography (PSG) at Peking University People's Hospital were recruited in this cross-sectional study. nGER presence was defined as typical nGER symptoms (heartburn or acid regurgitation occurring at night which affects sleep, with or without medication treatment) at least once a week in the past four weeks. A low ArTH was predicted based on the following PSG features: a total score of 2 or more, with one point assigned for each of the following criteria: apnea-hypopnea index (AHI) < 30/h, nadir oxygen saturation > 82.5 %, the proportion of hypopneas > 58.3 %, otherwise the ArTH was classified as high. Demographic and anthropometric characteristics, PSG parameters, and questionnaires related to clinical symptoms and comorbidities were obtained. The associations between nGER and clinical features were examined by multivariate logistic regressions.

RESULTS

The prevalence of typical nGER symptoms in patients with OSA was 17.8 %. High ArTH (P = 0.006), BMI ≥28 kg/m2 (P = 0.023), the Epworth Sleepiness Scale (ESS) Scores >16 (P = 0.006), and age over 60 years old (P = 0.002) were associated with a markedly increased risk of nGER in patients with OSA. Notably, in non-obese patients with OSA, a high ArTH not only significantly added to the presence of nGER (OR = 2.905, 95 % CI: 1.352-6.241, P < 0.01) after controlling for age, sex, ESS scores, comorbidities (including hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, and stroke) and total arousal index, but also associated with nGER symptom frequencies (OR = 2.856, 95 % CI = 1.118-7.294, P = 0.028) after adjusting for age, ESS scores, and medication use.

CONCLUSIONS

A high ArTH is independently associated with nGER in patients with OSA. For non-obese patients with OSA, a high ArTH is not only associated with the presence of nGER but also correlated with nGER symptom frequencies.

[Specialist Guidelines of The German Respiratory Society for Diagnosis and Treatment of adult Patients Suffering from Cough]

This is the 4th edition of the Cough Guidelines of the German Respiratory Society written by respiratory, gastroenterology, ear-nose-throat specialists, including respiratory physiotherapists and speech pathology specialists; importantly, a patient representative was also involved.Compared with earlier versions we used a new methodology: after discussion in the guidelines group, we asked and answered the 12 most important and most frequent "key" questions regarding the clinical practice. The extent of the guideline could thus be significantly reduced.We added a short scientific background to each of the answers including the most recent references. The recommendations and statements were created in consensus and graded as strong, or weak. If sufficient literature was not available, we suggested discussing joint decisions with the patient.The 12 key questions are as follows:- Key question 1: The classification of cough (acute, i. e. up to three weeks duration; chronic, i. e. after 8 weeks duration and subacute in between) did not change, but we added "cough with or without expectoration as an additional classification aspect with therapeutic consequences.- Key question 2: Acute and subacute cough are mostly (but not exclusively) due to the common cold. They are the first or second most frequent symptom prompting patients to seek medical (or pharmacist's) care. Antibiotic therapy is strongly discouraged for common cold- Key question 3: We defined "Red flags" for mandatory immediate diagnostic for acute cough, which usually does not require such diagnostic procedures- Key question 4: Chronic cough overview of the most common causes for- Key question 5: Cough in acute SARS-CoV-2 infection and in long COVID - Key question 6: Refractory chronic cough and idiopathic chronic cough, two recently established entities were explained more in detail- Key question 7: To upper airway cough syndrome - Key question 8: Gastro-oesophageal-reflux-related cough - Key question 9: Cough-variant asthma and non-asthmatic eosinophilic bronchitis - Key question 10: Overview of drugs causing cough - Key question 11: Basic and personalized (due to the individual history) diagnostic procedures for patients with cough- Key question 12: Physiotherapy, speech therapy and pharmacotherapy for cough.

Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression

BACKGROUND

Reflux-like symptoms and reflux oesophagitis are often perceived as having the same acid-related aetiology and responsiveness to antisecretory therapy. However, the frequency of residual symptom reporting on proton pump inhibitor (PPI) therapy suggests the two entities have some differential pathophysiological determinants requiring distinct management approaches.

AIMS

To examine the complexities of reflux-like symptom pathophysiology and strategies that may be used to target contributing factors beyond acid reflux.

METHODS

A panel of ten expert clinicians (primary care, gastroenterology and psychology) held a series of online meetings to share perspectives on the underlying contributors to, and management of, reflux-like symptoms when PPIs are ineffective or provide partial relief. This review summarises the agreed key themes that emerged from the expert discussions.

RESULTS

While degradation of the anti-reflux barrier dominates in reflux oesophagitis, cognitive-affective, behavioural, and other psychosocial factors can play a major role in symptom persistence. These require individualised management strategies, beginning with education on the gut-brain connection and expectation setting with regard to PPI therapy. A detailed clinical history and patient-reported outcome tools that measure symptom burden and associated anxiety/hypervigilance can help guide management using brain-gut behavioural therapies, supported diet/lifestyle modification, diaphragmatic breathing, weight loss, and/or on-demand symptom control measures according to a patient's specific needs.

CONCLUSIONS

A paradigm shift in reflux-like symptom management is required such that acid suppression is viewed as one of several interventions that can be utilised as part of a phenotype-driven, individualised approach to care that acknowledges the multiple contributors to symptom burden.

Shared genetic architecture of gastroesophageal reflux disease and age related phenotypes

Increasing age is a risk factor of gastroesophageal reflux disease. This study aims to uncover the shared genetic architecture of gastroesophageal reflux disease (GERD) and age-related phenotypes. Based on publicly available GWAS statistics, this genome-wide pleiotropic association research was performed with multiple genetic approaches sequentially to explore the pleiotropic associations from single-nucleotide polymorphism (SNP) and gene levels, to reveal the underlying shared genetic etiology between GERD and age-related phenotypes. This study featured shared genetic mechanisms between GERD and age-related phenotypes, including frailty index (FI), telomere length (TL), longevity, and parental lifespan (PL). Strong genetic association were observed. A set of pleiotropic loci and genes were identified by PLACO, FUMA, Bayesian colocalization and additional MAGMA analysis. Our research provided strong evidence of genetic correlation between GERD and several age-related phenotypes, especially frailty index (FI) and telomere length (TL), brought novel insight into the shared genetic architecture between GERD and aging.

Potassium-competitive Acid Blockers for Treatment of Extraesophageal Symptoms and Signs

Extraesophageal symptoms and signs of gastroesophageal reflux disease (GERD), such as throat clearing, globus sensation, hoarseness, cough, asthma, pulmonary fibrosis, otitis, sinusitis, and dental erosions, are common and pose diagnostic and therapeutic challenges. Proton pump inhibitors (PPIs) are the mainstay of treatment for GERD, but have demonstrated a limited effectiveness for extraesophageal symptoms and signs in several meta-analyses. Potassium-competitive acid blockers (P-CABs) offer more rapid and sustained acid inhibition than PPIs; therefore, P-CABs may have the potential to be at least as good or superior to PPIs in relieving extraesophageal symptoms and signs of GERD. To date, there have been 4 prospective randomized trials demonstrating similar efficacy of P-CABs to PPIs in the treatment of extraesophageal symptoms and signs, but more rapid and greater efficacy in patients with severe symptoms. Therefore, P-CABs appear to have a treatment role in extraesophageal symptoms and signs of GERD. However, considering that P-CABs are not superior to PPIs, large-scale, multi-center studies with double dose P-CABs over a prolonged period of time may elucidate a subgroup of patients in whom P-CABs are beneficial in ameliorating extraesophageal symptoms and signs.

Increased Prevalence of Barrett's Esophagus in Taiwan: A Prospective Multicenter Study

BACKGROUND AND AIM

With rising rates of esophageal adenocarcinoma (EAC) in Western countries, Barrett's esophagus (BE) has become a growing concern. The increasing prevalence of chronic gastroesophageal reflux disease (GERD) in Taiwan suggests a potential rise in BE cases as well. A 2007 large-scale study reported a BE prevalence of 1.06% in Taiwan. Our multicenter prospective study aims to evaluate the current prevalence of BE and identify key risk factors in this region.

METHOD

We assessed outpatients undergoing upper gastrointestinal endoscopy for various symptoms, obtaining biopsies from endoscopically suspected esophageal metaplasia (ESEM) at least 1 cm above the gastroesophageal junction. Quadrant biopsies were taken every 2 cm, with BE confirmed by histological evidence of specialized intestinal metaplasia.

RESULTS

Among 8697 subjects, the prevalence of BE was 2.6%. GERD symptoms, erosive esophagitis (EE), and hiatal hernia (HH) were present in 52.5%, 27.3%, and 7.85% of subjects, respectively. Of 751 with ESEM, 228 were diagnosed with BE, predominantly short-segment BE (78.1%). Multivariate analysis identified significant risk factors for BE: age > 50 (OR = 1.59), male gender (OR = 2.27), alcohol consumption (OR = 1.70), GERD symptoms (OR = 1.45), EE (OR = 1.94), and HH (OR = 2.49) (all p < 0.01).

CONCLUSION

The prevalence of BE was identified as 2.6%, representing a significant increase compared with 2007. Significant risk factors include age more than 50, male gender, alcohol use, GERD symptoms, EE, and HH.

Wear behavior of 3D printed, minimally invasive restorations: Clinical data after 24 months in function

STATEMENT OF PROBLEM

The prevalence of pathological tooth wear and a reduced vertical dimension of occlusion has increased, but prosthetic rehabilitation concepts have been invasive, time-consuming, and expensive. How affordable, esthetic, and less invasive treatment concepts will perform remains unclear.

PURPOSE

The purpose of this proof-of-concept clinical study was to evaluate the wear behavior of 3-dimensionally (3D) printed, minimally invasive restorations fabricated from a ceramic- reinforced composite resin material after 24 months in clinical function.

MATERIAL AND METHODS

The study included 28 participants who received noninvasive 3D printed restorations made of a computer-aided design and computer aided-manufacturing (CAD-CAM) ceramic-reinforced composite resin material (n=352). Maximum occlusal height loss and mean profile loss were measured by using an intraoral scanner and a matching software program (Geomagic Control X; 3D systems) by 1 clinician. Scans were conducted at baseline and after 12 and 24 months. A descriptive statistical analysis, including mean values, medians, standard deviations (SDs) interquartile range and 95% confidence interval (95% CI) were conducted (α=.05).

RESULTS

Maximum occlusal height loss and mean profile loss were analyzed. The molar restorations showed the highest mean values of maximum occlusal height loss after 12 (0.76 mm) and 24 (1.25 mm) months. The anterior restorations showed the lowest wear rates. In general, 123 restorations (35%) had material wear >0.5 mm and were classified as fractured after 24 months of clinical application. Most of the nonfractured restorations experienced localized material wear between 0.11 mm and 0.35 mm, whereas mean profile loss values varied between 0.05 mm and 0.11 mm.

CONCLUSIONS

Three-dimensionally printed, noninvasive restorations manufactured from a ceramic-reinforced composite resin material showed considerable material wear after 2 years of clinical function, and the material appears suitable only for interim restorations.

Association between an energy-adjusted inflammatory diet index and gastroesophageal reflux disease: a retrospective cohort study

PURPOSE

To examine and quantify the association between an inflammatory diet index and gastroesophageal reflux disease (GERD) utilizing extensive data from a large cohort.

METHODS

This study included eligible UK Biobank participants recruited between 2006 and 2010 who had no prior history of GERD and no missing data for key covariates. The primary outcome was incident GERD, identified using the "first occurrence" dataset. 27 eligible food/nutrient parameters derived from the 24-h recall questionnaires in the UK Biobank were included to calculate the energy-adjusted dietary inflammation index (E-DII) score. The E-DII score was employed as a continuous variable in restricted cubic spline regression (RCS) analysis. To facilitate analysis, participants were then categorized into four groups based on quartile values in the subsequent Cox regression analysis adjusting varying degrees of confounding factors.

RESULTS

After exclusion, 154,590 participants were included in the primary analysis. Over a mean 12.36-year follow-up, a total of 12, 041(7.79%) participants experienced GERD. The results of multivariable RCS showed that the risk of GERD had a slightly overall increased trend along with E-DII after adjusting the confounding factors. The cumulative incidence of GERD in the four groups was significantly different (P < 0.001) and participants in higher quartiles determined by E-DII had a higher GERD incidence. Results from both univariate and multivariate Cox regression consistently revealed the most pro-inflammatory E-DII group (i.e. the fourth quartile) had a significantly heightened risk of GERD compared to those in the first quartile (crude HR [95% CI] 1.118 [1.063-1.175]; fully adjusted HR [95% CI] 1.136 [1.079-1.196]). Subgroup analyses revealed variations across populations, while sensitivity analyses confirmed the robustness of primary findings.

CONCLUSIONS

The current study revealed that that adherence to a diet with high pro-inflammatory potential might be associated with higher GERD incidence and further randomized controlled trials are needed to provide more conclusive evidence.

[GERD-associated laryngeal granuloma: a series of clinical observations. Case report]

Laryngeal granuloma is a benign neoplasm located on the vocal processes of the arytenoid cartilage. The causes of development may be prolonged or traumatic intubation (23%), gastroesophageal reflux disease leading to chronic cough (30%), excessive vocal load (33%); respectively, post-intubation, contact and idiopathic granulomas are distinguished. In laryngopharyngeal reflux, an extraesophageal manifestation of gastroesophageal reflux disease, morphological changes in the mucous membrane of the larynx and pharynx occur as a result of direct exposure to acidic stomach contents, pepsin, bile and pancreatic enzymes that cause the development of contact laryngeal granuloma. Diagnosis of laryngopharyngeal reflux includes analysis of the patient's life history, registration of complaints using questionnaires, assessment of the clinical and functional state of the larynx using visual analog scales of reflux signs, the use of instrumental methods and laboratory tests. The latter determine the acidity of gastric juice, bile acids, pepsin, as well as the presence of Helicobacterpylori. Instrumental methods include esophagogastroduodenoscopy, videolaryngostroboscopy, esophageal manometry and 24-hour pH impedancometry - the most accurate method for diagnosing reflux in the esophagus, regardless of the pH of the bolus. During videolaryngostroboscopy in patients with the laryngopharyngeal reflux, laryngeal lesion is often detected in the form of swelling, hyperplasia of the mucous membrane of the intercostal fold and posterior vocal folds. The treatment of patients with laryngeal contact granulomas is based on a combination of antireflux therapy and phonopedia. Surgical intervention is necessary only in the case of large granuloma sizes for morphological verification and restoration of glottis patency. Complex rational therapy of patients with laryngopharyngeal reflux, including the use of proton pump inhibitors, prokinetics and antacids, can increase the effectiveness of surgical treatment of patients with laryngeal granuloma and reduce the risk of recurrence. The own clinical observations presented in the article emphasize the importance of an interdisciplinary approach of laryngologists and gastroenterologists to the diagnosis and treatment of patients with reflux-associated laryngeal granulomas, which makes it possible to minimize and in some cases avoid surgery.

Gastroesophageal reflux during postpyloric versus gastric tube feeding in preterm infants with bronchopulmonary dysplasia

BACKGROUND

Whether postpyloric feeding reduces gastroesophageal reflux (GER) in very preterm infants with bronchopulmonary dysplasia (BPD) is uncertain.

METHODS

Prospective observational study comparing GER profiles measured using 24-h esophageal pH-impedance monitoring in infants with BPD receiving clinically prescribed postpyloric (n = 21) or gastric (n = 24) tube feeding.

RESULTS

Participants (median gestational age 25.0 weeks, IQR 24.1-26.9) underwent testing at a median postmenstrual age of 46.6 weeks (IQR 42.7-52.4). The number of GER episodes recorded by impedance varied widely (median 27, range 1-195). Postpyloric versus gastric feeding was associated with fewer GER episodes (median, IQR: 16, 5-41 vs. 40, 19-60; p = 0.07) and less exposure of the proximal esophagus to reflux (median duration, IQR: 0.1 min, 0.005-0.6 vs. 0.77 min, 0.16-1.8; p = 0.045), but a higher proportion of acidic (pH < 4) GER episodes (median, IQR: 91%, 70-100 vs. 31%, 16-54; p < 0.001).

CONCLUSION

Postpyloric feeding may reduce total GER burden but increase the relative proportion of acidic GER in infants with BPD.

Diagnosis and Management of Gastroesophageal Reflux Disease: A Concise Review for Clinicians

Gastroesophageal reflux disease (GERD) is a clinical condition seen frequently by both primary care providers and gastroenterologists. Although it is incredibly common, the diagnosis and management of GERD are not always straightforward. In this review, we summarize the symptoms, pathophysiologic process, and risk factors for GERD. We outline a stepwise approach for the diagnosis of GERD, accounting for the presence of typical and atypical symptoms, in the context of alarm symptoms and comorbid conditions. We also outline an approach to management of GERD based on the results of diagnostic work-up, including the presence or absence of GERD-related complications, symptom severity, and response to recommended medical therapy. On completion of this article, clinicians should be able to select the appropriate diagnostic and treatment pathways for patients with GERD. Clinicians should also be able to properly identify when to refer a patient with GERD to a gastroenterologist.

Computed tomography roadmap for post-operative fundoplication imaging with a novel structured reporting checklist

INTRODUCTION

With increasing numbers and acceptability of laparoscopic anti-reflux surgery (LARS) procedures over long-term medical treatment in the past decade, it follows that the complications of fundoplication wrap are seen intermittently with recurrent symptoms of heartburn and dysphagia. Endoscopy and barium swallow are the initial investigations performed for suspected fundoplication wrap failures. However, with easy availability of multislice computed tomography (CT) and the multiplanar reconstructions along with reduction in familiarity with barium examinations, it would be prudent for the surgeons to familiarise themselves with various appearances of wrap failure. Currently, there is no accepted standard to report a fundoplication wrap failure. We did a thorough literature review on the use of CT scans for fundoplication wrap failure, created a multidisciplinary hernia team with prominent radiologists and surgeons and discussed the role of CT scans in the management of suspected wrap failure. After completing a pilot study with around 43 patients of wrap failure, we created a standard CT reporting format which helped us in the management of even the most complex cases. This standard reporting format can be used by trainees and surgeons worldwide. This would lead to uniformity in reporting, would help in decision-making and would also help create national and international primary wrap failure and redo fundoplication registry.

PATIENTS AND METHODS

A total of 43 patients of wrap failure of multislice CT evaluation were analysed for type of failure along with factors responsible for the maintenance of integrity of the wrap. A novel checklist with structured reporting was used for the description of the post-operative imaging findings.

RESULTS

The demographic characteristics, post-operative imaging and intraoperative findings were described. The different types of wrap failure - Hinder types and associated pathologies were analysed for relative frequency in wrap failures. The novel structured reporting included wrap integrity and failure complications in post-operative patients of LARS.

CONCLUSION

Fundoplication wrap failure is not an uncommon complication seen after LARS. A novel structured report with checklist will help the surgeons to evaluate the post-operative patient with recurrent symptoms. Multislice CT is the ideal modality for imaging suspected wrap failures after primary endoscopic evaluation. Multiplanar imaging with coronal and sagittal reconstructions is useful for understanding the integrity of the wrap and its ability to detect failure/migration.

Is gastroesophageal reflux disease a comorbidity of burning mouth syndrome? A cross-sectional, real-world study

BackgroundThe etiology of burning mouth syndrome (BMS) patients remains unclear and systemic conditions concurrently with BMS are viewed with greater scrutiny. The present study aimed to reveal whether gastroesophageal reflux disease (GERD) is the possible comorbidity of BMS.MethodsIn our study, a real-world design was employed, enrolling BMS patients from an oral medicine clinic and capturing data in a non-interventional, cross-sectional setting. Endoscopy and the Gastroesophageal Reflux Disease Questionnaire (GERDQ) were used to assess the potential GERD patients. Demographics, clinical symptoms and signs were compared between both the GERD and non-GERD groups, and GERDQ ≥8 and <8 groups. Meanwhile, GERDQ items were assessed to determine predictive value.ResultsIn total, 124 BMS patients with GERDQ scores were enrolled, of whom 84 patients were screened by endoscopy. GERD were confirmed by endoscopy in 30.95% (26/84) of patients with BMS, whereas 69.05% (58/84) showed no definite evidence of GERD. When GERDQ with a cutoff score of 8 was utilized for screening all 124 BMS patients, 25.8% (32/124) had GERDQ scores ≥8. When considering the endoscopic diagnosis as the golden standard due to the low availability of 24-h pH monitoring, the specificity and sensitivity were 79.2% and 46.2% respectively. Clinically, altered taste (p = 0.022) and thickened tongue coating (p = 0.001) were significantly more common in the GERDQ ≥8 group, whereas no significant difference was revealed between endoscopy approved GERD and non-GERD groups.ConclusionsGERD may represent a potential systemic comorbidity in BMS patients and GERDQ might serve as the screening tool assisting healthcare professionals. Altered taste and thickened tongue coating might be suggestive for potential GERD symptoms in BMS patients. Further research is desired to elucidate the mechanisms linking such conditions.

Socioeconomic Determinants of Health and Reflux Management: Insights from a Tertiary Medical Center

OBJECTIVES

To assess the correlation of social determinants of health (SDOH) with the general care patterns related to gastroesophageal reflux disease and laryngopharyngeal reflux. Determine correlation of SDOH on utilization rates for medication, reflux testing and surgical intervention for patients diagnosed with reflux. Describe overall care patterns for gastroesophageal reflux disease care at a tertiary academic facility.

STUDY DESIGN

Retrospective chart review.

METHODS

Patient demographics (age, sex, race, ethnicity, and insurance status) were extracted for adults diagnosed with reflux between 2009 and 2019. Odds ratios (ORs) for the associations between sociodemographic factors and reflux treatment pathways were determined by chi-square analyses.

RESULTS

A total of 143,786 patients were evaluated during the study period with a diagnosis code of reflux. A subgroup of 40,754 patients had objective reflux testing including Bravo, dual pH-impedance, manometry, esophagogastroduodenoscopy (EGD) and esophagram, but no significant difference in utilization rates was found. A total of 239 patients who failed medical management underwent fundoplication. White (OR 2.43, 95% confidence interval [CI] 1.56-3.70) and female (OR 1.37, 95% CI 1.05-1.79) patients were more likely to undergo fundoplication than Black (OR 0.42, 95% CI 0.25-0.70) and male (OR 0.72, 95% CI 0.55-0.95) patients. Patients with private insurance (OR 1.58, 95% CI 1.23-2.04) were more likely to undergo fundoplication than those with public insurance (OR 0.65, 95% CI 0.50-0.84). Male patients were less likely to undergo fundoplication (OR 0.69, 95% CI 0.49-0.98) among patients evaluated for reflux with EGD.

CONCLUSIONS

SDOH correlate with patterns of reflux evaluation and management at our tertiary care center.

LEVEL OF EVIDENCE

4 Laryngoscope, 135:1335-1342, 2025.

A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (X842) and Lansoprazole for the Treatment of Patients With Erosive Esophagitis

INTRODUCTION

X842 is a new type of gastric acid-suppressing agent with a rapid onset of action and a long duration of effect. We aim to investigate the efficacy and safety of different doses of X842 vs lansoprazole in the treatment of patients with erosive esophagitis (EE).

METHODS

This phase 2 study included 90 patients with EE (Los Angeles grades A-D) who were randomized (1:1:1) to receive oral low-dose X842 (50 mg/d, n = 31), high-dose X842 (100 mg/d, n = 31), or lansoprazole (30 mg/d, n = 30) for 4 weeks. The main efficacy end point was the EE healing rate, which was the proportion of patients who achieved endoscopic healing after 4 weeks of treatment.

RESULTS

For intention-to-treat analysis, the EE healing rates at 4 weeks were 93.6% (29/31), 79.3% (23/29), and 80.0% (24/30) for the X842 50 mg, the X842 100 mg, and the lansoprazole 30 mg groups. For per-protocol analysis, the EE healing rates at 4 weeks were 93.6% (29/31), 80.8% (21/26), and 82.1% (23/28) in the 3 groups, respectively. The EE healing rate did not significantly differ among the 3 groups in either the intention-to-treat ( P = 0.2351) or per-protocol ( P = 0.3320) analysis. The incidence of drug-related treatment-emergent adverse events did not differ among groups. No severe drug-related treatment-emergent adverse events occurred in the X842 group.

DISCUSSION

Our findings confirmed that X842 had efficacy and a favorable safety profile similar to those of lansoprazole. Therefore, X842, a novel potassium-competitive acid blocker, is expected to become a promising therapeutic agent for EE.

Evaluation of the Susceptibility of Bangladeshi University Students to Gastroesophageal Reflux Disease (GERD) and Its Associated Factors: A Cross-Sectional Study

Background and Aims

Gastroesophageal reflux disease (GERD) is a highly prevalent clinical condition all over the world. The study was conducted to determine the GERD prevalence among Bangladeshi university students using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) score and to find out what factors are linked to the disease.

Methods

The study was based on descriptive cross-sectional analysis. After a comprehensive literature review, a questionnaire was developed with some pre-structured options kept in the sociodemographic, dietary, and lifestyle sections along with the FSSG parameters. The tool was disseminated among students of different universities in Bangladesh. After receiving the responses, all the data was analyzed using SPSS software (version 26.0).

Results

After scrutiny, 402 responses of the study participants were subjected to statistical analysis, and among participants, 57.2% (N = 230) were female and 42.8% (N = 172) were male. The GERD prevalence was 45.5% (N = 183), which indicated the FSSG score was more than 8 among 45.5% of the individuals. Logistic regression analysis revealed that eating beyond fullness (OR = 2.859, CI = 1.811-4.515), consumption of painkillers (OR = 2.237, CI = 1.370-3.653), anxiety (OR = 2.349, CI = 1.529-3.611), being stressed (OR = 2.255, CI = 1.456-3.494), quick eating habit (OR = 1.845, CI = 1.240-2.745), poor sleep quality (OR = 1.760, CI = 1.183-2.620), fast food consumption (OR = 1.613, CI = 1.082-2.404), eating sour and spicy food regularly (OR = 1.610, CI = 1.073-2.415), female gender (OR = 1.595, CI = 1.068-2.381), less interval between dinner and sleep (OR = 1.561, CI = 1.020-2.389), being alone most of the time (OR = 1.514, CI = 1.016-2.257), were significantly associated with the occurrence of GERD symptoms.

Conclusion

GERD symptoms were seen among a large number of university students. Various sociodemographic, dietary, and lifestyle-related factors had an impact on the disease; these contributing factors should be positively modified to alleviate the burden of GERD symptoms.

Long-term efficacy and quality of life after antireflux surgery

BACKGROUND

Antireflux surgery (ARS) has been found to be an effective treatment of gastro-esophageal reflux disease (GERD); however, the long-term effects are uncertain. This study aimed to evaluate the long-term efficacy of ARS on quality of life, symptom severity, and use of proton pump inhibitors (PPIs).

METHODS

A validated GERD Health-Related Quality of Life (GERD-HRQL) Questionnaire was sent to 419 patients who underwent ARS at Aarhus University Hospital from January 2012 to April 2020. Patient records were reviewed retrospectively. The Danish National Prescription Registry was used to collect data on the use of PPIs before and after ARS.

RESULTS

A response rate of 71% resulted in a total of 164 patients included in the study with a median follow-up time of 4.8 years (interquartile range: 2.5-6.7). The total GERD-HRQL median score at follow-up was 11.5 (IQR: 4-22). The proportion of patients experiencing daily symptoms of heartburn and regurgitation was significantly reduced pre- to postoperatively from 90 to 70% to 32% and 29%, respectively. Five years after surgery, 47% of patients had completely ceased PPI usage, while 44% were long-term users.

CONCLUSION

A lasting long-term effect of ARS on GERD symptoms was found, although almost a third of patients still experience heartburn and/or regurgitation daily. Almost half of patients were not taking PPIs 5 years after ARS, but 44% became long-term users. Patients should be made aware that long-term PPI therapy often is necessary following ARS.

Primary Peristalsis Is the Dominant Mechanism of Refluxate Clearance Following Gastroesophageal Reflux

BACKGROUND

Refluxate volume and pH drop following gastroesophageal reflux are mostly cleared by peristalsis. We evaluated the roles of primary volume clearing peristaltic wave (VCPW), secondary VCPW, post-reflux swallow-induced peristaltic wave (PSPW), and late primary peristaltic wave (LPPW) in refluxate clearance.

METHODS

We retrospectively analyzed pH-impedance studies performed off therapy in 40 patients with typical esophageal symptoms. Mechanism of refluxate clearance was evaluated for each reflux episode (primary VCPW vs. secondary VCPW vs. none), as well as presence of PSPW, LPPW when PSPW was absent, and pH recovery with each mechanism. Per-episode and per-patient analyses determined the dominant mechanism of refluxate clearance and pH recovery.

RESULTS

Of 958 reflux episodes, 88% were acidic. A primary VCPW was the dominant mechanism for volume clearance (48.4% acid, 47.8% non-acid reflux episodes), and ≥ 50% pH recovery (58.7%). Of reflux episodes lacking pH recovery, PSPW resulted in ≥ 50% pH recovery in 40.2%, and LPPW in 60.9%. In logistic regression models, primary peristaltic wave (primary VCPW, PSPW, or LPPW) had the highest likelihood of pH recovery in per-episode analysis (OR 2.1, CI 1.3-3.0, p < 0.001), and in per-patient analysis (OR 11.0, CI 1.5-20.5, p = 0.025), among which primary VCPW was the most effective (OR 3.4, CI 1.5-7.7, p = 0.003).

CONCLUSIONS

A primary peristaltic wave from a swallow, either in the form of a VCPW, PSPW, or LPPW, is the dominant mechanism of pH recovery after gastroesophageal reflux. When a primary VCPW does not correct pH drop, PSPW, and LPPW are equivalent salvage mechanisms for pH recovery.

NMDAR2B/PKA/CREB signaling pathway contributes to esophageal neuropathic pain in gastroesophageal reflux disease

BACKGROUND

Esophageal hypersensitivity is an important cause of refractory gastroesophageal reflux disease, in which patients do not respond to standard acid-suppressive therapy and suffer from continuous noncardiac chest pain and regurgitation. The N-methyl-D-aspartate receptor (NMDAR) may play a crucial role in the development of visceral hypersensitivity in functional gastrointestinal disorders. However, the specific mechanisms of visceral hypersensitivity in upper digestive tract diseases remain poorly understood.

AIM

To investigate the role of the NMDAR2B/protein kinase A (PKA)/cAMP-response element binding protein (CREB) signaling pathway in the development of esophageal neuropathic pain associated with gastroesophageal reflux disease (GERD).

METHODS

Thirty-six 6-week-old specific pathogen free rats were randomly assigned to six groups: the control, model, model + NMDAR agonist, model + NMDAR antagonist, model + PKA antagonist, and model + NMDAR antagonist + PKA agonist groups, with six rats in each group. The model was induced via an intraperitoneal injection of ovalbumin for sensitization along with local esophageal stimulation. Immunohistochemistry and Western blotting were utilized to assess the expression levels of NMDAR2B signaling pathway-related proteins in the cingulate gyrus, dorsal thalamus, spinal dorsal horn, and peripheral esophageal tissues. RT-PCR was used to measure the corresponding mRNA expression, and ELISA was used to determine the serum brain-derived neurotrophic factor (BDNF) concentration. Behavioral scoring was performed during balloon distention and acid perfusion of the lower esophagus.

RESULTS

Compared with the control group, the model group presented significantly increased expression levels of the NMDAR2B, PKA, CREB, BDNF, substance P, and calcitonin gene-related peptide proteins and mRNAs in the cingulate gyrus, dorsal thalamus, spinal dorsal horn, and lower esophagus (P < 0.05). Compared with the model group, the model + NMDAR agonist group exhibited even higher expression levels of these proteins and mRNAs (P < 0.05), whereas the model + NMDAR antagonist and model + PKA antagonist groups presented lower expression levels (P < 0.05). The model + NMDAR antagonist + PKA agonist group presented higher expression levels than did the model + NMDAR antagonist group (P < 0.05). The changes in the serum BDNF concentration and behavioral score during balloon distention and acid perfusion were consistent with these changes in expression.

CONCLUSION

The NMDAR2B signaling pathway plays a critical role in the development of neuropathic pain in GERD through the PKA/CREB/BDNF pathway.

Natural Products in the Management of Gastroesophageal Reflux Disease: Mechanisms, Efficacy, and Future Directions

Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder that is defined by the reflux of gastric contents into the esophagus, and it results in symptoms such as esophageal inflammation, regurgitation, and indigestion. Although proton pump inhibitors (PPIs) and histamine-2 receptor antagonists are frequently employed to treat GERD, their prolonged administration is associated with adverse effects, necessitating the development of alternative therapeutic strategies. Natural products are now recognized as promising candidates for the management of GERD due to their bioactive compounds, which possess antioxidant, anti-inflammatory, and mucosal-protective properties. The potential of natural products in the treatment of GERD is comprehensively examined in this review, with a focus on their mechanisms of action, which include acid suppression, esophageal mucosal regeneration, anti-inflammatory activity, and gut microbiota modulation. Also, the efficacy and safety of key natural products, including flavonoids, polyphenols, plant-derived oils, herbal extracts, probiotics, and dietary components, in preclinical and clinical studies, are assessed. Additionally, this review addresses the barriers confronting the translation of natural therapies into clinical practice, such as regulatory obstacles, variability in bioavailability, and the need for dosage standardization. The integration of natural products into the management of GERD has the potential to enhance conventional therapies, providing a more comprehensive and secure approach for patients.

Associations between gastroesophageal reflux disease and otolaryngological diseases

In this study, we conducted a 2-sample Mendelian randomization (MR) analysis to explore the relationship between gastroesophageal reflux disease (GERD) and 16 common otolaryngological diseases. Single-nucleotide polymorphisms that are strongly associated with GERD were used as instrumental variables. The primary estimation of the causal effect utilized the inverse variance weighting method, supplemented by MR Egger, weighted median, simple mode, and weighted mode as alternative methods for estimating the causal effect. Then, sensitivity analyses, including heterogeneity, pleiotropy, and leave-one-out analyses, were performed to verify the robustness of the results. The analysis of MR showed that genetically predicted GERD was associated with an increased risk of acute upper respiratory infection (odds ratios [OR] = 1.1418, 95% confidence intervals [CI] = 1.0664-1.2225, P = 1.00 × 10-4), chronic pharyngitis (OR = 1.483, 95% CI = 1.1495-1.9132, P = 2.40 × 10-3), vocal cord dysfunction (OR = 2.2963, 95% CI = 1.4174-3.7201, P = 7.00 × 10-4), sleep apnea (OR = 1.0022, 95% CI = 1.0009-1.0035, P = 8.00 × 10-4), acute sinusitis (OR = 1.3247, 95% CI = 1.1774-1.4905, P = 2.94 × 10-6), chronic sinusitis (OR = 1.3649, 95% CI = 1.1854-1.5715, P = 1.52 × 10-6), chronic suppurative otitis media (OR = 2.085, 95% CI = 1.3292-3.2704, P = 1.40 × 10-3). Further sensitivity analyses showed no evidence of pleiotropy. The results of this study indicate that GERD may contribute to the development of some otolaryngological diseases. Further research and mechanistic investigations are warranted to elucidate the underlying connections and potential therapeutic implications.

The Los Angeles-B esophagitis is a conclusive diagnostic evidence for gastroesophageal reflux disease: the validation of Lyon Consensus 2.0

Background and Aims

Recently, Lyon Consensus 2.0 recommended Los Angeles (LA)-B esophagitis as conclusive evidence and LA-A esophagitis as borderline evidence for gastroesophageal reflux disease (GERD). This study aimed to investigate the diagnostic value of LA-B and LA-A esophagitis.

Methods

Patients with typical reflux symptoms who underwent endoscopy examination and received acid-suppressive therapy from two tertiary hospitals [the First Affiliated Hospital of Sun Yat-sen University (Guangzhou, P. R. China) and the Third People's Hospital of Chengdu (Chengdu, P. R. China)] were retrospectively included. Acid-suppression response rates, endoscopy results, motility, and reflux parameters were compared between patients with different grades of esophagitis.

Results

In total, 401 patients were enrolled, among whom 254 were without reflux esophagitis (RE), 51 had LA-A esophagitis, 44 had LA-B esophagitis, and 52 had LA-C/D esophagitis. Patients with LA-B esophagitis and LA-C/D esophagitis had significantly higher acid-suppressive response rates than non-RE patients (P < 0.05), whereas no significant difference was found between patients with LA-A esophagitis and non-RE patients (non-RE vs LA-A vs LA-B vs LA-C/D: 52.4% vs 70.6% vs 75.0% vs 82.7%). Among patients with LA-A esophagitis, those with a number of reflux episodes that exceeded 80 per day (90.0% vs 52.4%, P = 0.044) or hypotensive esophagogastric junction (72.4% vs 52.4%, P = 0.040) had significantly higher acid-suppressive response rates than non-RE patients.

Conclusions

LA-B esophagitis can be regarded as conclusive evidence for GERD and initiate acid-suppressive therapy. LA-A esophagitis did not establish a definite GERD diagnosis alone. When combined with adjunctive or supportive evidence, the acid-suppressive therapy response rate of LA-A esophagitis improved.

The Expression of F2RL1, P2RX2, P2RX3 and P2RY2 in the Esophagus of Patients with Gastroesophageal Reflux Disease and Their Relationship to Reflux Symptoms-A Pilot Study

Background: The current treatment of gastroesophageal reflux disease (GERD) is focused on decreasing gastric acid secretion. However, there is still a group of patients that do not respond to conventional therapy. Proteinase-activated receptors and purinergic receptors have been implicated in inflammation, visceral hyperalgesia and esophageal hypersensitivity. The aim of this study was to evaluate the esophageal expression of PAR2 (F2RL1) and P2RX2, P2RX3 and P2RY2 in GERD patients. Methods: A total of 53 patients with GERD and 9 healthy controls were enrolled in this study. The expression of the studied receptors was quantified using real-time PCR on esophageal biopsies from the patients with GERD and healthy controls. The correlation between the dilated intracellular spaces (DIS) score and patients' quality of life was investigated. Results: PAR2 receptor expression was higher in ERD compared to NERD and controls (326.10 ± 112.30 vs. 266.90 ± 84.76 vs. 77.60 ± 28.50; NS). P2X2 exhibited the highest expression in NERD compared to ERD and controls (302.20 ± 82.94 vs. 40.18 ± 17.78 vs. 26.81 ± 10.27), similarly to P2Y2, which expression was higher in NERD than in ERD and controls (7321.00 ± 1651.00 vs. 5306.0 ± 1738.00 vs. 3476.00 ± 508.0). Conclusions: We found that the expression of F2RL1, P2RX2 and P2RY2 is positively correlated to the DIS score in GERD patients. Higher PAR2, P2X2 and P2Y2 expression could mediate the sensitization of the esophagus and may be associated with the higher intensity of symptoms perceived by NERD patients.

Insight into global burden of gastroesophageal reflux disease: Understanding its reach and impact

The exact worldwide prevalence of gastroesophageal reflux disease (GERD) remains uncertain, despite its recognition as a common condition. This conundrum arises primarily from the lack of a standardized definition for GERD. The gold standard diagnostic tests for GERD, such as pH impedance testing and endoscopy, are cumbersome and impractical for assessing community prevalence. Consequently, most epidemiological studies rely on symptom-based screening tools. GERD symptoms can be both esophageal and extraesophageal, varying widely among individuals. This variability has led to multiple symptom-based definitions of GERD, with no consensus, resulting in prevalence estimates ranging from 5% to 25% worldwide. Most systematic reviews define GERD as experiencing heartburn and/or regurgitation at least once weekly, yielding a calculated prevalence of 13.98%. In 2017, the global age-standardized prevalence of GERD was estimated at 8819 per 100000 people (95% confidence interval: 7781-9863), a figure that has remained stable from 1990 to 2017. Prevalence increases with age, leading to more years lived with disability. GERD significantly impairs quality of life and can lead to multiple complications. Additionally, it imposes a severe economic burden, with the United States alone estimated to spend around 10 billion dollars annually on diagnosis and treatment. In summary, GERD prevalence varies greatly by region and even within different areas of the same province. Determining the exact prevalence is challenging due to inconsistent diagnostic criteria. However, it is well-documented that GERD poses a significant global burden, affecting the quality of life of individuals and creating a substantial healthcare cost.

Adherence to global diet quality score in relation to gastroesophageal reflux disease and flatulence in Iranian adults

INTRODUCTION

Gastroesophageal reflux disease (GERD) and flatulence are both prevalent afflictions and negatively impact the quality of life. This study aims to determine the relationship between the Global Diet Quality Score (GDQS), a novel metric based on the Prime Diet Quality Score with GERD and flatulence in Iranian adults.

METHODS

The cross-sectional study was conducted among 6202 adults in the context of the Shahedieh cohort study accomplished. Dietary intakes of participants were collected by food frequency questionnaires (FFQs). To calculate GDQS, 25 food groups were comprised (16 healthy and 7 unhealthy food groups and two food groups categorized as unhealthy when consumed excessively). GERD and flatulence were assessed by a self-reported questionnaire. To examine the association between GDQS with GERD and flatulence, logistic regression was performed in crude and adjusted models (Model I: adjustments for age and energy intake; Model II: gender, physical activity, marital status, occupation, educational levels, WSI, and BMI; and Model III: smoking status, depression, diabetes, hypertension, and cardio events.) RESULTS: Participants in the highest quintile of GDQS had 20% higher odds of having GERD than individuals in the lowest one (OR: 1.20; 95% CI: 0.88-1.65, P trend = 0.508). Compared to the lowest quintile, the participants in the highest quintile had no significant reduction in probability of having flatulence in the crude model (OR: 0.94; 95% CI: 0.81-1.11, P trend = 0.578). These associations remained non-significant after adjustments for confounding variables.

CONCLUSION

No significant associations were observed between higher adherence to GDQS with odds of GERD and flatulence in Iranian adults. To better understand these findings, longitudinal studies especially randomized clinical trials are needed.

Efficacy of combined sleeve gastrectomy and nissen fundoplication for weight loss and prevention of postoperative gastroesophageal reflux disease in patients with obesity: a systematic review and meta-analysis

The addition of a Nissen fundoplication to the sleeve gastrectomy (SG) has been recently proposed to reduce the incidence of postoperative gastroesophageal reflux disease (GERD). The aim of this study was to assess the effectiveness and safety of laparoscopic Nissen Sleeve (LNS). A systematic review using the Medline database was performed to identify original articles analyzing outcomes after LNS. Main outcomes included weight loss, improvement of GERD symptoms, esophagitis, proton pump inhibitor (PPI) usage, and pH monitoring. Postprocedural complications were included as secondary outcomes. A meta-analysis of proportions and paired preintervention and postintervention tests were used to assess the effect of the procedure on the different outcomes. A total of 5 studies comprising 246 patients undergoing LNS were included in the analysis. Mean age was 43.22 (40-46.2) years and 201 (85.12%) were females. The mean preoperative body mass index (BMI) of patients was 38.10 (33.9-40.4) kg/m2. After a mean follow up of 27 (12-60) months, there was a significant reduction in mean BMI (pre: 38.10 versus post: 29.36, P < .007) and a mean excess weight loss (EWL) of 59.10% (26%-82%). The proportion of patients with GERD symptoms (pre: 80.16% versus post: 11.22%, P = .001) were significantly reduced after the operation. The use of PPIs (pre: 69% versus post: 8.98%, P = .10) and presence of esophagitis (pre: 69.6% versus post: 18%, P = .05) also reduced after the procedure, but this was not statiscally significant. Overall morbidity rate was 4% (95% confidence interval [CI], 1%-11%), with a weighted pooled proportion of 2% (95% CI, 0%-6%) for leaks, 2% (95% CI, 1%-5%) for strictures, 1% (95% CI, 1%-3%) for bleeding, and 3% (95% CI, 1%-5%) for perforation. LNS seems to be a safe and effective operation with apparently better GERD-related outcomes than SG alone. Further studies with longer follow-up and objective measurement of reflux are needed to confirm the successful outcomes of the procedure.

A Paper-Based Sensor for the Detection of Gastroesophageal Reflux Disease Utilizing a Cleavable Fluorescent Polymer

Nowadays, gastroesophageal reflux disease (GERD) has emerged as one of the major hazards to the health of the upper gastrointestinal tract, and there is an urgent need for a low-cost, user-friendly, and non-invasive detection method. Herein, a paper-based sensor (CP sensor) for the non-invasive screening of GERD is proposed. The sensor is structured as a specially shaped cellulose paper strip embedded with fluorescent colloids, which are self-assembled from a cleavable synthetic fluorescent polymer (P4). Benefiting from the introduction of amide bonds and the unique assembled structure of the nanocolloids, the pepsin in the sample solution will hydrolyze the water-soluble branches in the micellar shell during detection, resulting in a corresponding output of the fluorescent signal. This responsiveness, which can be observed by the naked eye, is so sensitive with a minimum detectable concentration for pepsin as low as 0.3 ng·mL-1. Clinical trials have further demonstrates that the designed paper sensor is capable of providing improved accuracy in the early diagnosis of GERD.

Topical Protection of Esophageal Mucosa as a New Treatment of GERD

Among the various factors implicated in the pathogenesis of gastroesophageal reflux disease (GERD), visceral hypersensitivity and mucosal resistance have been recently re-evaluated in relation to the increasing phenomenon of proton pump inhibitor failure, particularly in patients with nonerosive reflux disease (NERD). Intensive research has allowed us to understand that noxious substances contained in the refluxate are able to interact with esophageal epithelium and to induce the elicitation of symptoms. The frequent evidence of microscopic esophagitis able to increase the permeability of the mucosa, the proximity of sensory afferent nerve fibers to the esophageal lumen favoring the higher sensitivity to noxious substances and the possible activation of inflammatory pathways interacting with sensory nerve endings are pathophysiological alterations confirming that mucosal resistance is impaired in GERD patients. Accordingly, the reinforcement of protective mechanisms of esophageal mucosa by topical therapies has become a novel treatment target. Alginate, the combination of hyaluronic acid+chondroitin sulphate and Poliprotect have been shown to adhere to esophageal mucosa and to have good protective properties. Several placebo-controlled clinical trials have shown that these compounds, given alone or as add-on therapy for short periods, enable to relieve symptoms and to improve the quality of life in NERD patients. Further studies are needed to confirm the above results and to find new mucosal protectants in order to improve the management of NERD patients.

Management of Patients With Refractory Reflux-Like Symptoms Despite Proton Pump Inhibitor Therapy: Evidence-Based Consensus Statements

BACKGROUND

Many patients diagnosed with gastro-oesophageal reflux disease (GERD) have persistent symptoms despite proton pump inhibitor (PPI) therapy.

AIMS

The aim of this consensus is to provide evidence-based statements to guide clinicians caring for patients with refractory reflux-like symptoms (rRLS) or refractory GERD.

METHODS

This consensus was developed by the International Working Group for the Classification of Oesophagitis. The steering committee developed specific PICO questions pertaining to the management of PPI rRLS. Methodologists conducted systematic reviews of the literature. The quality of evidence and strength of recommendations were rated using the GRADE approach.

RESULTS

Consensus was reached on 13 of 17 statements on diagnosis and management. For rRLS, suggested diagnostic strategies included endoscopy, ambulatory reflux testing and oesophageal manometry. The group did not reach consensus on the role of oesophageal biopsies or the use of reflux-symptom association in patients undergoing reflux testing. The group suggested against increasing the PPI dose in patients who had received 8 weeks of a twice-daily PPI. Adjunctive alginate or antacid therapy was suggested. There was no consensus on the role of adjunctive prokinetics. There was little role for adjunctive transient lower oesophageal sphincter relaxation (TLESR) inhibitors or bile acid sequestrants. Endoscopic or surgical anti-reflux procedures should not be performed in patients with rRLS in the absence of objectively confirmed GERD.

CONCLUSIONS

The management of rRLS should be personalised, based on shared decision-making regarding the role of diagnostic testing to confirm or rule out GERD as a basis for treatment optimisation. Anti-reflux procedures should not be performed without objective confirmation of GERD.

Mean Nocturnal Baseline Impedance May Be Greater Than 2500 Ohms in Chinese Patients With GERD

BACKGROUND

According to the Lyon Consensus 2.0, mean nocturnal baseline impedance (MNBI) greater than 2500 Ω is considered evidence against gastroesophageal reflux disease (GERD). However, we have observed that a subset of GERD patients presents with MNBI exceeding 2500 Ω.

AIMS

To investigate MNBI characteristics in Chinese GERD patients, identify clinical features of those with normal MNBI, and examine factors influencing MNBI values.

METHODS

We retrospectively investigated 259 patients with typical reflux symptoms. Demographics, symptoms, proton pump inhibitor (PPI) response, esophageal motility parameters were compared between patients with different AET levels and MNBI levels.

RESULTS

Among the cohort, 38.2% had AET 4%-6%, and 37.5% had AET > 6%. Notably, 95.2% of patients with AET < 4%, 49.5% with AET 4%-6%, and 17.6% with AET > 6% had MNBI > 2500 Ω. Independent risk factors for MNBI > 2500 Ω included the number and duration of supine acid reflux and lower esophageal sphincter (LES) resting pressure. In GERD patients with heartburn, patients with MNBI ≤ 2500 Ω had higher PPI response than MNBI > 2500 Ω (81.1% vs. 55.6%, p = 0.009).

CONCLUSIONS

Approximately one-third of Chinese GERD patients have an MNBI > 2500 Ω. The thresholds of MNBI for supporting or ruling out GERD in the Chinese population should be adjusted. MNBI values are independently predicted by the severity of supine acid reflux and the LES resting pressure. GERD patients with mild supine acid reflux may still exhibit normal MNBI levels. Patients with lower MNBI values tend to show better responses to PPI therapy.

The Contemporary Diagnostic Approaches to Esophageal Symptomatology

Esophageal symptoms, including dysphagia, heartburn, and non-cardiac chest pain, are prevalent concerns in gastroenterology. This review examines the roles of advanced diagnostic modalities such as high-resolution manometry (HRM), pH-impedance monitoring, and EndoFLIP in understanding esophageal physiology and pathology. Here, we discuss the clinical presentations of common esophageal symptoms and explore how structural abnormalities like strictures and motility disorders, including achalasia and esophageal spasms, are assessed using these tools. The diagnostic utility of endoscopy in visualizing mucosal and structural changes is highlighted alongside emerging technologies like artificial intelligence in enhancing detection capabilities. Complementary techniques, such as barium esophagrams and reflux monitoring, provide additional functional and anatomical insights, crucial for comprehensive patient evaluation. The integration of these diagnostic approaches fosters a deeper understanding of esophageal disorders, guiding effective management strategies and improving patient outcomes. This review aimed to highlight the importance of adopting a multimodal diagnostic approach in modern gastroenterological practice.

American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for strategies to diagnose and manage GERD. This document was developed using the Grading of Recommendations Assessment, Development, and Evaluation framework and serves as an update to the 2014 ASGE guideline on the role of endoscopy in the management of GERD. This updated guideline addresses the indications for endoscopy in patients with GERD as well as in the emerging population of patients who develop GERD after sleeve gastrectomy or peroral endoscopic myotomy. It also discusses how to endoscopically evaluate gastroesophageal junctional integrity in a comprehensive and uniform manner. Importantly, this guideline also discusses management strategies for GERD including the role of lifestyle interventions, proton pump inhibitors (PPIs), and endoscopic antireflux therapy (including transoral incisionless fundoplication [TIF], radiofrequency energy, and combined hiatal hernia repair and TIF [cTIF]) in the management of GERD. The ASGE suggests upper endoscopy for the evaluation of GERD in patients with alarm symptoms, with multiple risk factors for Barrett's esophagus, and with a history of sleeve gastrectomy. The ASGE recommends careful endoscopic evaluation, reporting, and photo-documentation of objective GERD findings with attention to gastroesophageal junction landmarks and integrity in patients who undergo upper endoscopy to improve care. In patients with GERD symptoms, the ASGE recommends lifestyle modifications. In patients with symptomatic and confirmed GERD with predominant heartburn symptoms, the ASGE recommends medical management including PPIs at the lowest dose for the shortest duration possible while initiating discussion about long-term management options. In patients with confirmed GERD with small hiatal hernias (≤2 cm) and Hill grade I or II who meet specific criteria, the ASGE suggests evaluation for TIF as an alternative to chronic medical management. In patients with persistent GERD with large hiatal hernias (> 2cm) and Hill grade III or IV, the ASGE suggests either cTIF or surgical therapy based on multidisciplinary review. This document summarizes the methods, analyses, and decision processes used to reach the final recommendations and represents the official ASGE recommendations on the above topics.

American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: methodology and review of evidence

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for strategies to diagnose and manage GERD. This document was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and serves as an update to the prior ASGE guideline on the role of endoscopy in the management of GERD (2014). The updated guideline addresses the indications for endoscopy in patients with GERD, including patients who have undergone sleeve gastrectomy (SG) and peroral endoscopic myotomy (POEM). It also discusses endoscopic evaluation of gastroesophageal junctional integrity comprehensively and uniformly. Important, this guideline discusses management strategies for GERD including lifestyle interventions, proton pump inhibitors (PPIs), and endoscopic antireflux therapy including transoral incisionless fundoplication (TIF), radiofrequency energy, and TIF combined with hiatal hernia repair (cTIF). The ASGE recommends upper endoscopy for the evaluation of GERD in patients with alarm symptoms. The ASGE suggests upper endoscopy for symptomatic patients with a history of SG and POEM. The ASGE recommends careful endoscopic evaluation, reporting, and photo-documentation of objective GERD findings and gastroesophageal junction landmarks and integrity to improve patient care and outcomes. In patients with GERD symptoms, the ASGE recommends lifestyle modifications. In patients with symptomatic and confirmed GERD with predominant heartburn symptoms, the ASGE recommends medical management including PPIs at the lowest dose for the shortest duration while initiating discussion about long-term management options. In patients with confirmed GERD with small hiatal hernia (≤2 cm) and Hill grade I or II flap valve who meet specific criteria, the ASGE suggests evaluation for TIF as an alternative to long-term medical management. In patients with confirmed GERD with a large hiatal hernia (>2 cm) and Hill grade 3 or 4 flap valve, the ASGE suggests evaluation for combined endoscopic-surgical TIF (cTIF) in a multidisciplinary review. This document clearly outlines the methodology, analysis, and decision used to reach the final recommendations and represents the official ASGE recommendations on the above topics.

Baseline Impedance via Manometry Predicts Pathological Mean Nocturnal Baseline Impedance in Isolated Laryngopharyngeal Reflux Symptoms

Background/Aims

Distal mean nocturnal baseline impedance (MNBI) measuring via pH-impedance may be valuable in diagnosing patients with suspected laryngopharyngeal reflux (LPR). However, its wide adoption is hindered by cost and invasiveness. This study investigates whether baseline impedance measured during high-resolution impedance manometry (HRIM-BI) can predict pathological MNBI.

Methods

A cross-sectional study in Taiwan included 74 subjects suspected of LPR, who underwent HRIM (MMS) and pH-impedance testing (Diversatek), after stopping proton pump inhibitors for more than 7 days. Subjects with grade C or D esophagitis or Barrett's esophagus were excluded. The cohort was divided into 2 groups: those with concomitant typical reflux symptoms (CTRS, n = 28) and those with isolated LPR symptoms (ILPRS, n = 46). HRIM-BI measurements focused on both distal and proximal esophagi. Pathological MNBI was identified as values below 2065 Ω, measured 3 cm above the lower esophageal sphincter.

Results

In all subjects, distal HRIM-BI values correlated weakly with distal MNBI(r = 0.34-0.39, P < 0.005). However, in patients with ILPRS, distal HRIM-BI corelated moderately with distal MNBI(r = 0.43-0.48, P < 0.005). The areas under the receiver operating characteristic curve was 0.78 (P = 0.001) with a sensitivity of 0.83 and a specificity of 0.68. No correlation exists between distal HRIM-BI and distal MNBI in patients with CTRS, and between proximal HRIM-BI and proximal MNBI in both groups.

Conclusions

Distal HRIM-BI from HRIM may potentially predict pathological MNBI in patients with ILPRS, but not in those with CTRS. Future outcome studies linked to the metric are warranted.

Impact of Metabolic Health and Its Changes on Erosive Esophagitis Remission: A Cohort Study

Background/Aims

We aim to compare the remission of erosive esophagitis (EE) among individuals with different phenotypes based on their metabolic health and obesity status and investigate the impact of changes in metabolic health on the EE remission.

Methods

Asymptomatic adults (n = 16 845) with EE at baseline, who underwent follow-up esophagogastroduodenoscopy (EGD) were categorized into 4 groups as follows: metabolically healthy (MH) nonobese, metabolically unhealthy (MU) nonobese, MH obese, and MU obese. EE was defined as grade A or higher mucosal breaks observed using esophagogastroduodenoscopy.

Results

During a median follow-up of 2.2 years, the remission rates of EE were 286.4/103, 260.1/103, 201.5/103, and 219.9/103 person-years in MH nonobese, MU nonobese, MH obese, and MU obese groups, respectively. Multivariate-adjusted hazard ratios (95% CI) for EE remission among the MH nonobese, MU nonobese, and MH obese groups versus that of the MU obese group were 1.30 (1.23-1.37), 1.17 (1.12-1.23), and 0.98 (0.90-1.06), respectively, whereas those of the persistent MH, progression of MH to MU, and remission of MU to MH compared with the persistent MU group were 1.37 (1.23-1.52), 1.15 (1.01-1.30), and 1.28 (1.12-1.46), respectively. Increased EE remission in the persistent MH group was consistently observed in individuals with and without obesity (or abdominal obesity).

Conclusions

Metabolic health and nonobesity independently and favorably impact EE remission. Maintaining normal weight and healthy metabolic status may contribute to EE remission.

Randomized Multicenter Study to Evaluate the Efficacy and Safety of Fexuprazan According to the Timing of Dosing in Patients With Erosive Esophagitis

Background/Aims

Fexuprazan, a novel potassium-competitive acid blocker, was developed for treating acid-related disorders. Pharmacokinetic and pharmacodynamic properties of fexuprazan, unlike those of proton pump inhibitors, are independent of food effect. This study aims to evaluate differences in efficacy and safety of fexuprazan in patients with erosive esophagitis (EE) according to the timing of dosing.

Methods

In this multicenter, open-label noninferiority study, patients who had typical reflux symptoms with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg daily 30 minutes before or after meal. Treatment was completed after 2 weeks or 4 weeks when healing was endoscopically confirmed. The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy up to week 4. Safety endpoints included treatment-emergent adverse events (TEAEs).

Results

In the prior-to-meal group (n = 89) and after-meal group (n = 86), 4-week EE healing rates were 98.77% and 100.00% (difference, 0.01%; 95% CI, -0.01% to 0.04%) and 2-week EE healing rates were 95.77% and 97.14% (difference, 0.01%; 95% CI, -0.05% to 0.07%), respectively. TEAEs were 9.78% and 8.70% in the prior-to-meal group and the after-meal group, respectively.

Conclusions

Non-inferiority analysis revealed that taking fexuprazan after meal was non-inferior to taking fexuprazan before meals in patients with EE. The frequency of adverse events was similar between the 2 study groups. The drug is safe and effective for healing EE regardless of the timing of dosing.

[Efficacy and Safety of Dual Delayed-Release Formulation of Esomeprazole in Patients with Gastroesophageal Reflux Disease: A Multicenter, Prospective, Observational Study]

Background/Aims

Gastroesophageal reflux disease (GERD) is a chronic and recurrent condition requiring constant dietary management and medication. This study evaluated the efficacy and safety of HIP1601, a dual delayed-release formulation of esomeprazole, in patients with GERD in a clinical setting.

Methods

This prospective, multicenter, observational study was conducted at 309 medical institutions in Korea between June 2021 and March 2023. HIP1601 was administered at daily doses of 40 mg or 20 mg to 5,407 patients requiring treatment or prevention of erosive esophagitis. The primary outcome was the improvement rate of GERD symptoms at four weeks. GERD-related symptoms and treatment-emergent adverse events were also analyzed.

Results

This study included 5,282 patients in the safety analysis set and 5,232 in the full analysis set. At four weeks, the improvement rate of GERD symptoms was 92.1% (95% confidence interval [CI]: 91.3-92.8%). By eight weeks, the improvement rate increased to 94.6% (95% CI: 94.0-95.3%). After HIP1601 administration, the severity scores for all four GERD symptoms decreased to less than 1, with statistically significant changes in the scores (p<0.001). HIP1601 was well-tolerated, with minimal adverse events reported (0.17%), and the treatment-emergent adverse events were mild to moderate in severity.

Conclusions

HIP1601 showed strong efficacy and safety in managing GERD symptoms, with high rates of symptom relief at four and eight weeks. Its extended action and improved symptom control make it a promising therapeutic option for GERD patients.

Clinical and functional factors influencing the outcome of laparoscopic Nissen fundoplication

BACKGROUND AND AIM

Laparoscopic Nissen fundoplication (LNF) is the gold standard of antireflux surgery. Up to 30% of patients experience symptoms after surgery, with insufficient information available. The main objective is to evaluate epidemiological, clinical, and functional factors associated with symptoms after LNP.

METHODS

a retrospective case-control study including 79 operated patients (2015-2024). We assessed the relationship between epidemiological data, functional tests, and imaging study results with the occurrence of symptoms after LNF.

RESULTS

24 asymptomatic and 55 symptomatic patients were included. Functional and imaging tests were normal in the majority of asymptomatic patients. IRP-4s (95th percentile) in asymptomatic patients is 20.4 mmHg. Female gender (OR 4, 95%CI; 1.1-14), preoperative dysphagia (OR 8.2, 95%CI: 1.4-47.6), and IRP-4s (OR 1.2, 95%CI: 1-1.3) are independent factors for postoperative dysphagia. Type-III esophagogastric junction morphology on high-resolution manometry (OR 6.1, 95%CI: 2.1-18.1) is independently associated with GERD symptoms. AET showed a trend toward being an independent factor but did not reach statistical significance (OR 1.1, 95%CI:1-1.3). Hiatal hernia in the esophagogram was associated with reintervention (OR 5.5, 95%CI: 1.6-19.1).

CONCLUSIONS

Asymptomatic patients mostly have normal functional tests after LNF, although IRP-4s normal value (95th percentile) is higher than proposed in the Chicago Classification. Preoperative dysphagia and female gender are independent factors for postoperative dysphagia, which should be considered in the preoperative assessment. Functional and imaging tests are essential in evaluating patients with postoperative symptoms. Dysphagia is associated with higher IRP while GERD symptoms are related to type-III-EGJ on HRM. Similarly, a hiatal hernia on the esophagogram is associated with reintervention.

Poliprotect®, a Medical Device Made of Substances, Potently Protects the Human Esophageal Mucosa Challenged by Multiple Agents: Evidence from In Vitro and Ex Vivo Electrophysiological Models

The integrity of esophageal epithelial cells in patients with gastroesophageal reflux disease (GERD) or GERD-like symptoms is the first mechanism of protection to decrease the sensitivity to gastric reflux and heartburn symptoms. We investigated the protective effects of Poliprotect® (PPRO), a CE-marked medical device, on esophageal epithelial integrity using in vitro and ex vivo models. In vitro, the protective effects of PPRO were tested on Caco-2 cells. PPRO demonstrated safety and protection against oxidative damage induced by hydrogen peroxide. It also preserved epithelial integrity by maintaining transepithelial electrical resistance (TEER) against damage from calcium removal or bile acid exposure (taurodeoxycholic acid, TDCA). Ex vivo, esophageal biopsies from patients subjected to endoscopy were mounted in Ussing chambers and exposed to damaging agents (HCl or HCl + TDCA). Untreated biopsies (control) showed significant loss of epithelial resistance (up to -33%). In contrast, low concentrations of PPRO (50-100 µg/mL) provided strong protection against these damages (p < 0.001), even after 60 min of washing. Histological analysis confirmed the barrier-enhancing effect of PPRO. Overall, PPRO effectively protected the esophageal epithelium from damage in both models, suggesting its potential role in alleviating GERD or GERD-like symptoms by strengthening mucosal barriers and reducing epithelial sensitivity to reflux.

Therapeutic Management of Gastroesophageal Reflux Disease (GERD)-Is There Something Between PPI and Fundoplication? An Overview

Gastroesophageal reflux disease (GERD) affects millions globally, with traditional treatments like proton pump inhibitors (PPIs) and surgical fundoplication presenting challenges such as long-term medication dependency and disturbing long term side effects following surgery. This review explores emerging, alternative therapies that offer less invasive, personalized alternatives for GERD management. Endoscopic approaches, including Stretta therapy, transoral incisionless fundoplication (TIF), and endoscopic full-thickness plication (EFTP), demonstrate promising but also controversial outcomes in symptom relief and reduced acid exposure. Laparoscopic electrical stimulation therapy (EndoStim®) and the LINX® magnetic sphincter augmentation system address LES dysfunction, while endoscopic anti-reflux mucosectomy and/or ablation techniques aim to construct a sufficient acid barrier. The RefluxStop™ device offers structural solutions to GERD pathophysiology with intriguing results in initial studies. Despite promising results, further research is required to establish long-term efficacy, safety, and optimal patient selection criteria for these novel interventions. This review underscores the importance of integrating emerging therapies into a tailored, multidisciplinary approach to GERD treatment.